Sulfonylureas Market By Drug Type (First-Generation Sulfonylureas [Tolbutamide, Chlorpropamide], Second-Generation Sulfonylureas [Glimepiride, Gliclazide, Glipizide, Glyburide]); By Therapy Type (Monotherapy, Combination Therapy [Metformin, DPP-4 Inhibitors]); By Formulation (Immediate-Release Tablets, Modified-Release Tablets); By Application (Type 2 Diabetes Mellitus, Neonatal Diabetes Mellitus); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

How Are Affordable Diabetes Medicines and Combination Treatments Sustaining the Sulfonylureas Market? – (Updated On: 8th-Oct-2026)

The Global Sulfonylureas Market was valued at USD 3.27 billion in 2025 and is projected to reach USD 3.81 billion by 2032, growing at a CAGR of 2.2% during 2026–2032, according to Strategic Market Research.

 

Sulfonylureas are a class of oral medicines used to treat Type 2 diabetes by helping the pancreas release more insulin, which lowers blood sugar levels.

 

In the United States, sulfonylureas continue to serve a substantial patient population. According to the Clin Cal Drug Stats Database, updated in August 2026 using AHRQ prescription data, approximately 4.76 million patients received sulfonylureas in 2024, accounting for an estimated 17.92 million prescriptions across the two medicines reported in its latest class totals. Glipizide represented approximately 12.81 million prescriptions, while glimepiride accounted for 5.11 million.

 

Internationally, sulfonylurea utilization remains particularly significant across several Asian healthcare markets. A multicountry study published in Diabetes, Obesity and Metabolism examined 62,512 patients with Type 2 diabetes across 11 Asian countries and regions. Among patients receiving oral glucose-lowering treatment, 59.4% were prescribed sulfonylurea-based therapy. Gliclazide accounted for 46.7% of sulfonylurea users, followed by glimepiride at 40.0% and glibenclamide at 8.1%. These historical clinical findings demonstrate substantial treatment adoption, particularly in markets where affordable oral diabetes medicines remain widely prescribed.

 

Overall, the Sulfonylureas Market continues to rely on established prescription volumes, affordable generic medicines, and combination therapy for Type 2 diabetes management. While newer diabetes treatments are gradually changing prescribing patterns, sulfonylureas remain relevant in cost-sensitive healthcare systems.

 

Which Sulfonylureas Market Subsegments Lead in Revenue and Which Are Growing the Fastest?

By Drug Type: Second-Generation Sulfonylureas Hold the Commercial Lead

Largest and Fastest-Growing Subsegment: Second-Generation Sulfonylureas

Second-generation sulfonylureas dominate the global Sulfonylureas Market, accounting for an estimated 98.0% market share, valued at USD 3.205 billion in 2025, and are projected to expand at a CAGR of 2.3% during 2026–2032. Their strong market position is supported by higher potency and effective blood glucose control at significantly lower doses than first-generation drugs. Widely prescribed medications such as glimepiride, glipizide, and gliclazide stimulate pancreatic insulin release, while their affordability and widespread generic availability sustain their use in Type 2 diabetes management.

 

By Therapy Type: Combination Regimens Capture the Largest Treatment Opportunity

Largest and Fastest-Growing Subsegment: Combination Therapy

Combination therapy with sulfonylureas holds a leading position in the Sulfonylureas Market, accounting for an estimated 61.0% market share, valued at USD 1.995 billion in 2025, and is projected to expand at a CAGR of 2.8% during 2026–2032. Sulfonylureas are commonly prescribed alongside metformin to address both insufficient insulin secretion and insulin resistance in type 2 diabetes. Their established clinical use, affordability, and ability to improve glycemic control when single-drug treatment becomes inadequate continue to support their widespread adoption in combination regimens.

 

By Formulation: Immediate-Release Tablets Lead as Modified-Release Options Gain Ground

Largest Subsegment: Immediate-Release Tablets

Immediate-release (IR) tablets remain the leading formulation in the Sulfonylureas Market, accounting for an estimated 72.0% market share, valued at USD 2.354 billion in 2025, and are projected to grow at a CAGR of 1.4% during 2026–2032. Their established role in type 2 diabetes treatment is supported by rapid absorption and stimulation of insulin release from pancreatic beta cells, helping lower blood glucose levels. Widespread generic availability, affordable treatment costs, and established prescribing practices continue to sustain their market position.

Fastest-Growing Subsegment: Modified-Release Tablets

Modified-release (MR) tablets are gaining importance in the Sulfonylureas Market, accounting for an estimated 28.0% market share, equivalent to USD 0.916 billion in 2025, and are projected to register the fastest CAGR of 4.1% during 2026–2032. Gliclazide MR remains a prominent formulation, providing gradual drug release over 24 hours to support more consistent blood glucose control. Its once-daily dosing convenience and potentially lower hypoglycemia risk compared with certain immediate-release sulfonylureas are encouraging wider clinical adoption and supporting sustained growth in modified-release formulations.

 

By Application: Type 2 Diabetes Anchors Use as Neonatal Treatment Opens a Specialized Opportunity

Largest Subsegment: Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus dominates the global Sulfonylureas Market, accounting for an estimated 99.7% market share, valued at USD 3.260 billion in 2025, with a projected CAGR of 2.2% during 2026–2032. Sulfonylureas remain an established oral treatment option for managing Type 2 Diabetes Mellitus by stimulating pancreatic beta cells to release insulin and lower blood glucose levels. Their affordability, widespread availability, and established clinical use continue to support prescriptions, particularly in cost-sensitive healthcare systems where access to newer diabetes medications remains limited.

Fastest-Growing Subsegment: Neonatal Diabetes Mellitus

Neonatal Diabetes Mellitus represents an estimated 0.3% share of the global Sulfonylureas Market, contributing approximately USD 0.010 billion in 2025, and is projected to register the fastest CAGR of 6.0% during 2026–2032. Oral sulfonylureas can replace daily insulin injections in up to 90% of infants with neonatal diabetes caused by specific genetic mutations, particularly those affecting KATP channels. Increasing genetic diagnosis and the ability to transition eligible infants from insulin therapy to oral treatment are creating specialized growth opportunities for sulfonylurea manufacturers.

 

By Distribution Channel: Retail Pharmacies Lead as Digital Refills Accelerate

Largest Subsegment: Retail Pharmacies

Retail pharmacies dominate the Sulfonylureas Market, accounting for an estimated 73.0% market share, valued at USD 2.387 billion in 2025, and are projected to grow at a CAGR of 2.1% during 2026–2032. Their leading position is supported by regular prescription refills, pharmacist-led medication counseling, and widespread availability of affordable oral diabetes treatments. Long-term sulfonylurea use among patients with type 2 diabetes creates consistent prescription volumes, while established pharmacy networks improve treatment accessibility and support continued medication use across urban and rural populations.

Fastest-Growing Subsegment: Online Pharmacies

Online pharmacies are emerging as the fastest-growing distribution channel in the Sulfonylureas Market, accounting for an estimated 9.0% market share, valued at USD 0.294 billion in 2025, and projected to expand at a 5.0% CAGR during 2026–2032. Mail-order prescription services, automatic refills, and competitive generic drug pricing are improving access to sulfonylureas for patients managing type 2 diabetes. Growing adoption of digital prescription platforms and home delivery services is encouraging repeat purchases of commonly prescribed medications such as glimepiride and gliclazide, supporting steady pharmacy sales growth.

 

By Geography: Asia-Pacific Leads Through Affordable Diabetes Treatment

Largest and Fastest-Growing Regional Market: Asia-Pacific

Asia-Pacific holds an estimated 43.0% market share, equivalent to USD 1.406 billion in 2025 revenue, and is projected to expand at a CAGR of 3.3% during 2026–2032. According to the IDF Diabetes Atlas, the Western Pacific region had approximately 215 million adults with diabetes in 2024, while Southeast Asia accounted for another 107 million. These IDF regions do not exactly match the commercial Asia-Pacific market boundary, but their substantial patient populations highlight the region's treatment opportunity. Affordable generic sulfonylureas remain important in markets where medication costs influence long-term diabetes management.

 

How Are Leading Pharmaceutical Companies and Formulation Innovations Shaping Competition in the Sulfonylureas Market?

Sanofi — Glimepiride and Fixed-Dose Combination Formulations

Sanofi participates in the market through its Amaryl portfolio, including glimepiride monotherapy and combination formulations for Type 2 Diabetes. Its Amaryl M tablets combine 1 mg or 2 mg of glimepiride with 500 mg of prolonged-release metformin, while Amaryl M Forte offers combinations containing 1,000 mg of sustained-release metformin. Sanofi also lists Amaryl MV, combining glimepiride, metformin, and voglibose. These formulations allow the company to participate in combination treatment, where multiple glucose-lowering mechanisms are used in a single prescription product.

Servier — Modified-Release Gliclazide Technology

Servier maintains a differentiated position through its Diamicron portfolio, particularly modified-release gliclazide formulations. Diamicron MR is available in 30 mg and 60 mg strengths, with approved daily doses ranging from 30 mg to 120 mg in relevant markets. Its controlled drug-release technology supports once-daily administration. Servier has also completed a 36-participant bioequivalence study comparing a single 120 mg modified-release tablet with two 60 mg tablets. Formulation development remains commercially relevant as manufacturers seek greater treatment convenience within an established drug category.

Pfizer — Established Glipizide and Extended-Release Products

Pfizer participates through Glucotrol (glipizide) and Glucotrol XL, which are indicated for improving glycemic control in adults with Type 2 Diabetes. Glucotrol XL uses extended-release formulation technology, providing an alternative to conventional immediate-release treatment. Pfizer's established product portfolio highlights the continued commercial role of branded sulfonylureas, although generic competition places pressure on pricing and branded-product differentiation.

Other Pharmaceutical Participants and Their Market Roles:

• Dr. Reddy's Laboratories: Participates in the generic antidiabetic pharmaceutical sector, where affordable oral formulations and distribution capabilities are important competitive factors.

• Torrent Pharmaceuticals: Competes in India's chronic-disease and generic formulation market, with established pharmaceutical manufacturing and distribution operations.

• Merck & Co.: Has a broader Type 2 Diabetes portfolio, including treatments outside the sulfonylurea class, making it more relevant as a therapeutic competitor than as a confirmed leading sulfonylurea supplier.

 

Analyst Commentary: Can Combination Treatments and Modified-Release Tablets Sustain Sulfonylureas Growth?

The Sulfonylureas Market is increasingly shaped by treatment affordability, changing diabetes prescribing patterns, and competition from newer glucose-lowering therapies. The strongest opportunities lie in cost-effective combination treatments, modified-release formulations, and expanding access to diabetes care across emerging economies. Although hypoglycemia risks and the growing preference for GLP-1 and SGLT2 therapies limit market expansion, sulfonylureas retain an important role in long-term Type 2 Diabetes management, particularly where medication costs and treatment accessibility influence prescribing decisions.

 

Sulfonylureas Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 3.27 Billion
Revenue Forecast in 2032	USD 3.81 Billion
Overall Growth Rate	CAGR of 2.2% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million/Billion, CAGR (2026 – 2032)
Segmentation	By Drug Type, By Therapy Type, By Formulation, By Application, By Distribution Channel, By Geography
By Drug Type	First-Generation Sulfonylureas (Tolbutamide, Chlorpropamide), Second-Generation Sulfonylureas (Glimepiride, Gliclazide, Glipizide, Glyburide)
By Therapy Type	Monotherapy, Combination Therapy (Metformin, DPP-4 Inhibitors)
By Formulation	Immediate-Release Tablets, Modified-Release Tablets
By Application	Type 2 Diabetes Mellitus, Neonatal Diabetes Mellitus
By Distribution Channel	Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Region	Asia-Pacific, North America, Europe, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Large Type 2 diabetes patient population, continued use of affordable generic oral diabetes medicines, established sulfonylurea prescribing practices, demand for combination therapy, treatment intensification among patients requiring additional glycemic control, increasing adoption of modified-release formulations, growing genetic diagnosis of neonatal diabetes, and expanding digital prescription and home-delivery channels
Customization Option	Available upon request